This article is more than 5 years old. Information may no longer be current.

VIDEO: Researchers explore use of virus-like particles in chikungunya vaccine development

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BALTIMORE — Barney S. Graham, MD, PhD, deputy director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, discusses a virus-like, particle-based chikungunya vaccine currently under phase 2 evaluation that can induce neutralizing antibodies similar to those in convalescent patients.

“We’re hopeful that within another 2 to 3 years, we can have an efficacy signal for whether this type of vaccine for chikungunya might work,” he says.

Disclosures: Graham reports no relevant financial disclosures.